Venturi Wealth Management LLC Has $110,000 Position in Option Care Health, Inc. (NASDAQ:OPCH)

Venturi Wealth Management LLC grew its holdings in Option Care Health, Inc. (NASDAQ:OPCH) by 2,621.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,735 shares of the company’s stock after purchasing an additional 4,561 shares during the period. Venturi Wealth Management LLC’s holdings in Option Care Health were worth $110,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. FMR LLC raised its holdings in shares of Option Care Health by 134.0% during the third quarter. FMR LLC now owns 7,516,448 shares of the company’s stock worth $235,265,000 after acquiring an additional 4,304,896 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Option Care Health by 4,432.8% during the 3rd quarter. Victory Capital Management Inc. now owns 1,621,593 shares of the company’s stock worth $50,756,000 after purchasing an additional 1,585,818 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Option Care Health by 15.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,924,915 shares of the company’s stock valued at $310,650,000 after buying an additional 1,328,326 shares during the last quarter. Geneva Capital Management LLC bought a new stake in shares of Option Care Health in the 3rd quarter valued at approximately $24,679,000. Finally, Westfield Capital Management Co. LP grew its stake in shares of Option Care Health by 10.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 6,492,152 shares of the company’s stock valued at $203,204,000 after buying an additional 599,589 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Bank of America upgraded shares of Option Care Health from a “neutral” rating to a “buy” rating and lifted their target price for the company from $26.00 to $33.00 in a research note on Monday, January 13th. UBS Group initiated coverage on shares of Option Care Health in a report on Thursday, December 5th. They set a “neutral” rating and a $26.00 price target on the stock. Barrington Research upped their price objective on shares of Option Care Health from $32.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday, January 14th. Jefferies Financial Group upgraded Option Care Health from a “hold” rating to a “buy” rating and raised their target price for the company from $26.00 to $35.00 in a report on Thursday, January 23rd. Finally, Truist Financial reduced their price target on Option Care Health from $41.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Option Care Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.25.

Option Care Health Price Performance

Shares of NASDAQ:OPCH opened at $32.00 on Monday. The business’s 50 day moving average is $27.71 and its 200-day moving average is $27.97. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $5.45 billion, a PE ratio of 26.89, a PEG ratio of 2.30 and a beta of 1.35. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $34.63.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.